Allogene Therapeutics (ALLO) Assets Average (2018 - 2026)

Allogene Therapeutics (ALLO) has 9 years of Assets Average data on file, last reported at $405.9 million in Q1 2026.

• For the quarter ending Q1 2026, Assets Average fell 23.17% year-over-year to $405.9 million; the trailing twelve-month figure through Mar 2026 stood at $405.9 million (down 23.17% YoY), and the FY2025 full-year result was $482.3 million, down 19.05% from the prior year.
• Assets Average eased to $405.9 million in Q1 2026, from $427.8 million in the prior quarter.
• In the past five years, Assets Average ranged from a high of $1.0 billion in Q1 2022 to a low of $405.9 million in Q1 2026.
• A 5-year average of $674.0 million and a median of $618.0 million in 2024 frame the typical range for Assets Average.
• Peak annual rise in Assets Average reached 14.03% in 2025, while the deepest fall reached 26.35% in 2025.
• Tracing ALLO's Assets Average over 5 years: stood at $858.0 million in 2022, then fell by 20.97% to $678.1 million in 2023, then slipped by 16.1% to $568.9 million in 2024, then slipped by 24.8% to $427.8 million in 2025, then slipped by 5.12% to $405.9 million in 2026.
• Business Quant data shows ALLO's Assets Average at $405.9 million in Q1 2026, $427.8 million in Q4 2025, and $455.2 million in Q3 2025.